Rodloff C, Koch D, Schauann R. Epidemiology and antifungal resistance in invasive candidiasis[J]. Eur J Med Res, 2011, 16(4): 187.
[2]
Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study[J].J Antimicrob Chemother, 2013, 68(7):1660.
[3]
Cannon R D, Fischer F J, NⅡmi K, et al. Drug pumping mechanisms in Candida albicans[J]. Nihon Ishinkin Gakkai Zasshi, 1998, 39(2):73.
[4]
Zhang X, Guo H, Gao L, et al. Molecular mechanisms underlying the tetrandrine-mediated reversal of the fluconazoleresistance of Candida albicans[J].Pharm Biol, 2013, 51(6):749.
[5]
Wu X Z, Chang W Q, Cheng A X, et al. Plagiochin E, an antifungal microcyclic bis(bibenzyl), induced apoptosis in Candida albicans through a metacaspase-dependent apoptotic pathway[J]. Biochim Biophys Acta, 2010, 1800(4):439.
[6]
Wang H, Xiao M, Chen S C, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol, 2012, 50(12):3952.
[7]
Szilágyi J, F ldi R, Bayegan S, et al. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology[J].J Chemother, 2012, 24(1):18.
[8]
Li J, Li L, Feng C, et al. Novel polyoxins generated by heterologously expressing polyoxin biosynthetic gene cluster in the sanN inactivated mutant of Streptomyces ansochromogenes[J]. Microb Cell Fact, 2012, 11:135.
[9]
Cho J, Hwang I S, Choi H, et al. The novel biological action of antimicrobial peptides via apoptosis induction[J]. J Microbiol Biotechnol, 2012, 22(11):1457.
[10]
Pfaller M A, Diekema D J, Gibbs D L, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion[J]. J Clin Microbiol, 2010, 48(4):1366.
Chen L M, Xu Y H, Zhou C L, et al. Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations[J]. J Int Med Res, 2010, 38(2):536.
[13]
Alexander B D, Johnson M D, Pfeiffer C D, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated MIC[J]. Clin Infect Dis, 2013, 56(12) 1724.
[14]
Pappas P G, Kauffman C A, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America[J]. Clin Infect Dis, 2009, 48(5):503.
[15]
Quan H, Cao Y Y, Xu Z, et al. Potent in vitro synegrism of flueonazole and beberine chloride against clinical isolates of Candida albicans resistant to fluconazole[J].Antimicrob Agents Chemother, 2006, 50(3):1096.
Huang S, Cao Y Y, Dai B D, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole[J]. Biol Pharm Bull, 2008, 31(12):2234.
[18]
Fu Z, Lu H, Zhu Z, et al.Combination of baicalein and amphotericin B accelerates Candida albicans apoptosis[J].Biol Pharm Bull, 2011, 34(2):214.
[19]
An M, Shen H, Cao Y, et al. Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans[J]. Int J Antimicrob Agent, 2009, 33(3):258.
[20]
Jin J, Guo N, Zhang J, et al. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans[J]. Lett Appl Microbiol, 2010, 51(3):351.
Sun L, Sun S, Cheng A, et al. In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans[J]. Antimicrob Agents Chemother, 2009, 53(4): 1586.
[25]
Guo N, Liu J, Wu X, et al.Antifungal activity of thymol against clinical isolates of fluconazole-sensitive and -resistant Candida albicans[J]. J Med Microbiol, 2009, 58(8):1074.
[26]
Khan M S, Ahmad I. Antibiofilm activity of certain phytocompounds and their synergy with fluconazole against Candida albicans biofilms[J]. J Antimicrob Chemother, 2012, 67(3):618.
[27]
Odds F C.Snyegry, antagonism, and what the chequerboard Puts bewteen them[J].J Antimicrob Chemother, 2003, 52(1):1.
[28]
Rózalska B, Sadowska B, Wieckowska-Szakiel M, et al. The synergism of antifungals and essential oils against Candida spp. evaluated by a modified gradient-diffusion method[J]. Med Dosw Mikrobiol, 2011, 63(2): 163.
Zhang H, Gao A, Li F, et al. Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps[J]. Yakugaku Zasshi, 2009, 129(5):623.
[31]
Guo X L, Leng P, Yang Y, et al. Plagiochin E, a botanic-derived phenolic compound, reverses fungal resistance to fluconazole relating to the efflux pump[J].J Appl Microbiol, 2008, 104(3):831.
Farrugia G, Balzan R.Oxidative stress and programmed cell death in yeast[J]. Front Oncol, 2012, 2:64.
[36]
Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation[J].J Proteome Res, 2009, 8(11): 5296.
[37]
Wu X Z, Cheng A X, Sun L M, et al. Effect of plagiochin E, an antifungal microcyclic bis(bibenzyl), exerts its antifungal activity through mitochondrial dysfunction-induced reaetive oxygen species accumulation in Candida albicans[J].Biochim Biophys Acta, 2009, 1790(8):770.
[38]
Wu X Z, Cheng A X, Sun L M, et al. Effect of plagiochin E, an antifungal microcyclic bis(bibenzyl), act on cell wall chitin synthesis in Candida albicans[J]. Acta Pharm Sin, 2008, 29:1478.
[39]
Sun L M, Cheng A X, Wu X Z, et al. Synergistic mechanisms of retigeric acid B and azoles against Candida albicans[J]. J Appl Microbiol, 2010, 108(1):341.
Yu L H, Wei X, Ma M, et al. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm[J]. Antimicrob Agents Chemother, 2012, 56(2): 770.
[43]
Lei G, Dan H, Jinhua L, et al. Berberine and itraconazole are not synergistic in vitro against Aspergillus fumigatus isolated from clinical patients[J]. Molecules, 2011, 16(11): 9218.
